Drugs / mRNA-1443
last change Oct 2020 re-read 2 minutes ago

mRNA-1443

Vaccine

Developed for
cytomegalovirus infection
Investigated by
ModernaTX, Inc.

Trials 1 · a red edge is where a trial was stopped

201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03382405 Nov 2017 → Oct 2020 cytomegalovirus infection ModernaTX, Inc. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as mRNA-1443 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03382405
Modality Vaccine “Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults” NCT03382405